Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir

Interim results of Abbott’s PROGRESS study showed that Kaletra® combined with raltegravir suggested a more rapid initial viral load decline when compared to a traditional triple-drug combination therapy of Kaletra and Truvada®.

Source: Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir